• Acute graft-versus-host disease (GVHD) [ Designated as safety issue: No ]
  
• Grade of acute GVHD [ Designated as safety issue: No ]
  
• Response criteria for treatment of acute GVHD [ Designated as safety issue: No ]
  
• Chronic GVHD [ Designated as safety issue: No ]
  
• Grade of chronic GVHD [ Designated as safety issue: No ]
  
• Response criteria for treatment of chronic GVHD [ Designated as safety issue: No ]
  
• Infections (i.e., bacterial, fungal, or viral) [ Designated as safety issue: No ]
  

OBJECTIVES:

• To evaluate the ability of the ImmuKnow® test to predict the onset and severity of acute or chronic graft-versus-host disease and/or measure the clinical effects of treatment.
• To evaluate the ability of the ImmuKnow test to predict the clinical response to immunosuppressive therapy.
• To evaluate the ability of the ImmuKnow test to predict infections among patients.

OUTLINE: Beginning on day 14 after allogeneic hematopoietic stem cell transplantation (HSCT), patients undergo blood sample collection at least once weekly for the first 100 days and then once to twice monthly for up to 1 year, in the absence of graft-versus-host disease (GVHD). If chronic or acute GVHD develops after day 100, more frequent blood sampling may occur. Blood sample collection is coordinated with the time of regular clinic visits to allow for evaluation of the clinical events recorded 2 weeks before and after the blood draw date. Blood samples are analyzed by the Cylex® and ImmuKnow® assays to measure global T-cell immune function and responsiveness to alterations in immunosuppressive post-HSCT therapy. Assay data obtained during the first 3 weeks and other post-transplant periods will be evaluated for possible correlations with clinical endpoints (i.e., GVHD incidence, rate of infection, and response to immunosuppressive therapy) to assess the predictive value of the assay.